CD40LG and myeloid sarcoma: Longitudinal studies to measure both IgM and IgG classes of APLA in larger cohorts of patients with relapsing-remitting MS are necessary to establish the significance of these autoantibodies and assess their pattern of expression before and after treatment with disease modifying agents.